The brightest star in Boston’s rapidly growing biotech scene isn’t a flashy new player, but rather one of its longest standing companies. While many biotech stocks have struggled this year ...

Biogen and City Therapeutics, a privately held developer of RNA-based “trigger molecules,” announced a partnership to develop ...

“Lots of companies are limping along,” said Mani Foroohar, senior research analyst at Boston health care investment bank Leerink Partners. Foroohar, a top biotech analyst, has slapped an ...

The greater Boston area is home to close to one thousand biotech companies. While Boston has long been a center of the life sciences, it has largely expanded thanks to huge government investments ...

The company will engage in BIO One-on-One Partnering™ meetings as it advances Phase 1 for Ketamir-2, prepares Phase IIa study ...

Boston Scientific is pulling its latest transcatheter aortic heart valve platform from the worldwide market and said it will ...

A few weeks after releasing disappointing data from its norovirus vaccine trial, a Boston biotech is cutting its workforce. A few weeks after releasing disappointing data from its norovirus ...

The Boston-based cell programming and biosecurity company had said the cuts were coming during quarterly earnings call earlier this year. Ginkgo Bioworks Holdings Inc. is headquartered in the ...

A Nurturing Force in Boston's Biotech Ecosystem Cambridge Scientific has emerged as a trusted partner in the region's booming biotech industry. Founded in 1997 by CEO Barb Pearlman, the company's ...

Biotechnology company Regeneron Pharmaceuticals is buying 23andMe for $256 million, two months after the genetic testing ...

In August, a single email triggered a chain of hand-wringing and strategizing inside one of America’s largest medical technology companies: A reporter asked Boston Scientific if the biotech ...